Clinical Trial Detail

NCT ID NCT02474173
Title Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

Therapies

Paclitaxel

Onalespib

Age Groups: adult senior

No variant requirements are available.